Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR3230(2)] to FES
- Suitable for: WB, IP, Flow Cyt, ICC/IF
- Reacts with: Human
Product nameAnti-FES antibody [EPR3230(2)]
See all FES primary antibodies
DescriptionRabbit monoclonal [EPR3230(2)] to FES
Tested applicationsSuitable for: WB, IP, Flow Cyt, ICC/IFmore details
Unsuitable for: IHC-P
Species reactivityReacts with: Human
Synthetic peptide within Human FES aa 750-850. The exact sequence is proprietary.
- TF-1, U937, and Human spleen lysates; HeLa cells
Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Reproducibility is key to advancing scientific discovery and accelerating scientists’ next breakthrough.
Abcam is leading the way with our range of recombinant antibodies, knockout-validated antibodies and knockout cell lines, all of which support improved reproducibility.
We are also planning to innovate the way in which we present recommended applications and species on our product datasheets, so that only applications & species that have been tested in our own labs, our suppliers or by selected trusted collaborators are covered by our Abpromise™ guarantee.
In preparation for this, we have started to update the applications & species that this product is Abpromise guaranteed for.
We are also updating the applications & species that this product has been “predicted to work with,” however this information is not covered by our Abpromise guarantee.
Applications & species from publications and Abreviews that have not been tested in our own labs or in those of our suppliers are not covered by the Abpromise guarantee.
Please check that this product meets your needs before purchasing. If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, as well as customer reviews and Q&As.
Storage instructionsShipped at 4°C. Store at -20°C. Stable for 12 months at -20°C.
Storage bufferpH: 7.20
Preservative: 0.01% Sodium azide
Constituents: 9% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA, 50% Tissue culture supernatant
Concentration information loading...
PurityTissue culture supernatant
Our Abpromise guarantee covers the use of ab108418 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/1000 - 1/10000. Detects a band of approximately 93 kDa (predicted molecular weight: 93 kDa).|
|IP||1/10 - 1/100.|
|Flow Cyt||1/100 - 1/500.
ab172730 - Rabbit monoclonal IgG, is suitable for use as an isotype control with this antibody.
|ICC/IF||1/100 - 1/250.|
Sequence similaritiesBelongs to the protein kinase superfamily. Tyr protein kinase family. Fes/fps subfamily.
Contains 1 FCH domain.
Contains 1 protein kinase domain.
Contains 1 SH2 domain.
- Information by UniProt
- c-fes/fps protein antibody
- cFES antibody
- Feline sarcoma (Snyder Theilen) viral (v fes)/Fujinami avian sarcoma (PRCII) viral (v fps) oncogene homolog antibody
All lanes : Anti-FES antibody [EPR3230(2)] (ab108418) at 1/1000 dilution
Lane 1 : TF-1 lysate
Lane 2 : U937 lysate
Lane 3 : Human spleen lysate
Lysates/proteins at 10 µg per lane.
Predicted band size: 93 kDa
ab108418, at a 1/100 dilution, staining FES in HeLa (Human epithelial cell line from cervix adenocarcinoma) cells by Immunofluorescence.
ab108418 has not yet been referenced specifically in any publications.